# Forward Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/forward-pharma

- Industry: Pharmaceuticals
- Headquarters: Shenzhen, China
- Website: www.forward-pharm.com
- Total disclosed funding: $16M
- Latest round: Series B (Mar 3, 2026)
- Investors on record: 6

## About

Based in Shenzhen, China and founded in 2015, Shenzhen Fuwo Pharmaceutical Co., Ltd., dba Forward Pharma, operates as a provider of innovative anti-tumor drug that focuses on the research and development of drugs for tumors and autoimmune diseases. The company has been rated as a Specialized, Refined, Featured and Original SMEs and has branch offices in Shanghai and Beijing. It has cooperated with Wuxi AppTec Group, Crown Bioscience, Inc., etc. The Founder and CEO, Xu Liangliang, graduated with a Ph.D. from the Department of Biological Sciences and Technology of Tsinghua University. The Chief Scientific Officer, Zhu Chenggang, received his Ph.D. from UC Irvine School of Pharmacy and worked at Novartis and AstraZeneca. In March 2026, Forward Pharma closed Series B+ funding from new investor Wuchuang Capital.

The company's main products include the fourth generation lung cancer targeted therapy drug FWD1509, the third generation oral specific estrogen receptor degradation agent FWD1802 for the treatment of breast cancer, and the monoclonal antibody drug FWB1313 for two autoimmune diseases of severe asthma and atopic inflammation. Its products focus on treating diseases such as lung cancer and breast cancer.

The company generates revenue by providing anti-tumor small molecule drug.

## Funding rounds

- Series B, Mar 3, 2026 — Wuchuang Capital
- Series B, Jul 14, 2023 — Qihang Capital
- Series B, Jan 19, 2023 — Leaguer Group, V Fund, Shenzhen Nanshan Huirong Investment
- Series A, Sep 2, 2021, $16M — Leaguer Group, Sangel Capital
- Angel, Mar 22, 2019 — Leaguer Group

## Investors

- Leaguer Group (https://capitalatlas.ai/funds/leaguer-group) — Angel, Series A, Series B
- Sangel Capital (https://capitalatlas.ai/funds/sangel-capital) — Series A
- V Fund (https://capitalatlas.ai/funds/v-fund) — Series B
- Shenzhen Nanshan Huirong Investment — Series B
- Qihang Capital (https://capitalatlas.ai/funds/qihang-capital) — Series B
- Wuchuang Capital (https://capitalatlas.ai/funds/wuchuang-capital) — Series B